Eli Lilly and Company (NYSE:LLY) Position Increased by McLean Asset Management Corp

McLean Asset Management Corp raised its stake in Eli Lilly and Company (NYSE:LLY) by 1.8% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,439 shares of the company’s stock after buying an additional 26 shares during the period. McLean Asset Management Corp’s holdings in Eli Lilly and Company were worth $675,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently modified their holdings of the company. Silicon Valley Capital Partners acquired a new position in shares of Eli Lilly and Company in the first quarter worth about $25,000. Bogart Wealth LLC raised its stake in Eli Lilly and Company by 193.3% during the 1st quarter. Bogart Wealth LLC now owns 88 shares of the company’s stock valued at $30,000 after purchasing an additional 58 shares during the period. Laffer Tengler Investments purchased a new stake in shares of Eli Lilly and Company in the first quarter valued at $33,000. Raleigh Capital Management Inc. boosted its position in shares of Eli Lilly and Company by 156.4% in the first quarter. Raleigh Capital Management Inc. now owns 100 shares of the company’s stock worth $34,000 after buying an additional 61 shares during the period. Finally, Tanglewood Legacy Advisors LLC purchased a new position in shares of Eli Lilly and Company during the fourth quarter valued at $37,000. Institutional investors and hedge funds own 81.38% of the company’s stock.

Eli Lilly and Company Stock Down 2.7 %

Shares of LLY stock opened at $575.66 on Friday. Eli Lilly and Company has a one year low of $296.32 and a one year high of $601.84. The company has a debt-to-equity ratio of 1.63, a current ratio of 1.13 and a quick ratio of 0.87. The stock has a fifty day moving average price of $512.56 and a 200 day moving average price of $438.41. The stock has a market cap of $546.47 billion, a P/E ratio of 80.06, a price-to-earnings-growth ratio of 2.47 and a beta of 0.32.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Tuesday, August 8th. The company reported $2.11 EPS for the quarter, topping analysts’ consensus estimates of $1.98 by $0.13. The company had revenue of $8.31 billion during the quarter, compared to the consensus estimate of $7.58 billion. Eli Lilly and Company had a net margin of 22.01% and a return on equity of 65.00%. The firm’s revenue for the quarter was up 28.1% compared to the same quarter last year. During the same period last year, the firm earned $1.25 EPS. Analysts predict that Eli Lilly and Company will post 9.84 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, September 8th. Stockholders of record on Tuesday, August 15th were paid a $1.13 dividend. The ex-dividend date of this dividend was Monday, August 14th. This represents a $4.52 annualized dividend and a dividend yield of 0.79%. Eli Lilly and Company’s dividend payout ratio is currently 62.87%.

Insider Transactions at Eli Lilly and Company

In related news, major shareholder Lilly Endowment Inc sold 34,156 shares of the business’s stock in a transaction on Tuesday, June 20th. The stock was sold at an average price of $454.08, for a total value of $15,509,556.48. Following the sale, the insider now owns 101,387,286 shares of the company’s stock, valued at approximately $46,037,938,826.88. The sale was disclosed in a legal filing with the SEC, which is available through this link. In other news, CAO Donald A. Zakrowski sold 600 shares of Eli Lilly and Company stock in a transaction that occurred on Monday, August 21st. The shares were sold at an average price of $546.51, for a total value of $327,906.00. Following the completion of the transaction, the chief accounting officer now owns 5,378 shares in the company, valued at $2,939,130.78. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Lilly Endowment Inc sold 34,156 shares of the business’s stock in a transaction that occurred on Tuesday, June 20th. The stock was sold at an average price of $454.08, for a total value of $15,509,556.48. Following the completion of the transaction, the insider now directly owns 101,387,286 shares in the company, valued at $46,037,938,826.88. The disclosure for this sale can be found here. In the last ninety days, insiders sold 1,010,309 shares of company stock valued at $21,095,701,670. Corporate insiders own 0.13% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have commented on LLY. 22nd Century Group restated a “maintains” rating on shares of Eli Lilly and Company in a research report on Tuesday, June 27th. Bank of America raised their price target on shares of Eli Lilly and Company from $500.00 to $600.00 in a report on Wednesday, August 9th. Wells Fargo & Company upped their price objective on shares of Eli Lilly and Company from $500.00 to $615.00 and gave the company an “overweight” rating in a research note on Tuesday, August 8th. Barclays increased their target price on shares of Eli Lilly and Company from $500.00 to $590.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 9th. Finally, JPMorgan Chase & Co. boosted their price target on shares of Eli Lilly and Company from $510.00 to $600.00 and gave the company an “overweight” rating in a report on Wednesday, August 9th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and twenty have issued a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $532.78.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.